Keywords
Oligometastatic Disease, Radiomics, Liquid Biopsy, Immunophenotyping, Decision Support System
Overview
This CCCZ flagship project OMDZH aims to advance our clinical and biological understanding of oligometastatic disease and thereby improve patient selection and the design of personalized treatment strategies. Specifically, we aim to improve imaging- and tissue-based identification of oligometastatic cancer patients, who achieve a long-term survival benefit of definitive local therapy. Additionally, we aim to improve early response assessment by liquid-biopsy and develop a patient decision support system based on patient reported outcomes measures (PROMS) for designing a personalized systemic treatment strategy.
Aims
Aim 1 will use computational methods for quantitative analysis of longitudinal radiological images to describe the disease burden and its temporal dynamic more precisely. Aim 2 will perform compari-sons of matched pair tumor specimens of the resected primary tumor and metastases using targeted sequencing, as well as immunological and digital spatial profiling to investigate intra-patient cancer heterogeneity as novel prognostic and predictive marker. Aim 3 will use liquid biopsies before and after definitive local therapy to quantitatively assess response not only radiologically but on a molecu-lar level within the systemic compartment. Lastly, aim 4 will develop and evaluate patient decision support systems to complement the currently limited evidence about the optimal patient-specific systemic treatment strategy.
OMDZH will analyze oligometastatic lung cancer, head-and-neck cancer, and prostate cancer and therefore include large patient cohorts. Simultaneously, we will en-sure that the methodologies will be disease-agnostic, which will enable transfer of our experiences to other cancer entities, where we are facing similar challenges. Our strong track record in design & conduct of clinical trials and international leadership in the field of OMD research will be essential for prospective validation of our findings.
“We formed a multi-disciplinary and multi-professional project team to address the unique challenges of oligometastatic cancer patients. We are therefore convinced that OMDZH represents high impact and relevance, clinically for many cancer patients and scientifically for the CCCZ, making this a unique opportunity to become a true flagship project with national and international recognition.”
Matthias Guckenberger - Department of Radiation Oncology, USZ
Graphical abstract of OMD-ZH work packages
Principal investigator and project team
Prof. Dr. med. Matthias Guckenberger, Director CCCZ Outreach and Education, University Hospital Zurich, Department of Radiation Oncology, matthias.guckenberger@usz.ch
Prof. Dr. med. Isabelle Schmitt-Opitz, University Hospital Zurich, Department of Thoracic Surgery, isabelle.schmitt-opitz@usz.ch
Prof. Dr. Burkhard Becher, University of Zurich, Institute of Experimental Immunology, becher@immunology.uzh.ch
Prof. Dr. med. Dr. phil. Nikola Biller-Andorno, University of Zurich, Institute of Biomedical Ethics and History of Medicine, biller-andorno@ibme.uzh.ch
Funding Period: 1.7.2023-31.12.2026
Funding Volume: CHF 2.000.000
Funded by: University Medicine Zurich (UMZH), Comprehensive Cancer Center Zurich (CCCZ)
Further projects
CCCZ Investigator Initiated Trial
BRAVE-Lung
Robotic-assisted Bronchoscopic Radiofrequency Ablation for Very-Early Lung Cancer -A novel Cancer Therapy
CCCZ Leuchtturmprojekte
Interdisziplinäre Forschungsteams übertragen Erkenntnisse aus der Grundlagenforschung in die klinische Anwendung und entwickeln neue Behandlungskonzepte gegen Krebs.